In this trial, 112 patients with centrally confirmed PIK3CA mutations in tumor tissue were enrolled based on their previous treatment (CDKi + AI, CDKi + fulvestrant, or systemic chemotherapy or endocrine therapy): enrollment was completed in prior CDKi + AI and CDKi + fulvestrant SOC cohorts. The gene discussed is PIK3CA; the disease is neoplasm.